Clinical Imaging Performance Evaluation of a Multi-Knife-Edge Slit Collimator-based Prompt Gamma Ray Imaging System

基于多刀口狭缝准直器的瞬发伽马射线成像系统的临床成像性能评估

• 批准号: 10511964
• 负责人: Joshua William Cates
• 金额: $ 9.73万
• 依托单位: UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10511964
• 关键词: Address; Area; Biological; Cell Nucleus; Charge; Clinical; Collimator; Data; Deposition; Discipline of Nuclear Medicine; Dose; Ensure; Evaluation; Gamma Rays; Half-Life; Image; Imaging Techniques; Laboratories; Length; Location; Monitor; Neutrons; Outcome; Pathway interactions; Patient Transfer; Patients; Performance; Photons; Physiologic pulse; Positioning Attribute; Positron; Positron-Emission Tomography; Primary Neoplasm; Production; Protocols documentation; Protons; Radiation Toxicity; Radiation therapy; Radioisotopes; Real-Time Systems; Resolution; Site; System; Techniques; Time; Tissues; Travel; Treatment Protocols; Tumor Volume; advanced system; base; clinical imaging; clinically relevant; design; detector; imager; imaging approach; imaging modality; imaging system; improved; in vivo; in vivo imaging system; interest; irradiation; millimeter; millisecond; novel; particle; particle therapy; proton beam; proton therapy; prototype; statistics; therapy outcome; treatment site; two-dimensional

Project Summary Proton therapy’s intrinsic advantage over conventional radiotherapy is the ability to selectively deposit large amounts of dose within a primary tumor site or region of interest while minimizing dose to healthy tissue. To fully leverage this advantage, proton range must be precisely controlled, monitored, and verified. Small errors in particle delivery can result in significant dose delivered to healthy tissue and more importantly minimal dose delivered to target volume. However, there is a lack of clinical solutions for proton range verification. Current approaches employ either positron emission tomography (PET)-based or prompt gamma imaging (PGI)-based techniques, which exploit the secondary emissions from charge particle tracks. PET is enabled for proton range verification due to positron emitting nuclei created in the charge particle tracks. Unfortunately, radionuclides of interest for this technique can have a half-life as long as 20 minutes, wherein significant biological washout can occur, degrading the correlation between annihilation photon origin and the original proton track location. PGI presents the most promising opportunity for real-time, in vivo range verification for charge particle therapies, as the secondary emissions in this approach are produced on very short time scales (picoseconds-to-milliseconds). To address the need for a clinical in vivo range verification system, Lawrence Berkeley National Laboratory (LBNL) has developed a prototype imaging system based on a novel multi-knife-edge slit collimator for high energy gamma-rays in combination with pixelated scintillation detector readout. This prototype provides two- dimensional imaging of PGI tracks using this collimator. Preliminary evaluations of the imager with 50 MeV proton beams showed exceptional promise for imaging proton tracks via their prompt gamma emissions, including sub- mm precision for proton range quantification with proton statistics commensurate to those present during therapy. We propose to evaluate this prototype PGI system in clinically relevant beam energies, beam currents, and scenarios to demonstrate its performance capabilities in a clinical setting. Data from these evaluations will fully characterize the prototype system’s capabilities, highlight clinical utility, and also guide the design of an advanced clinical imaging system for real-time, in vivo proton range verification in a small modular platform that can be positioned about the patient and gantry for any treatment regimen.

项目摘要 质子疗法比常规放射疗法的内在优势是能够选择性地沉积大的能力 在原发性肿瘤部位或感兴趣的区域内的剂量量，同时最大程度地减少对健康组织的剂量。完全 利用此优势，必须精确控制，监测和验证质子范围。小错误 粒子递送会导致明显的剂量递送到健康组织，更重要的是最小剂量 传递到目标体积。但是，缺乏用于质子范围验证的临床解决方案。当前的 方法员工是正电子发射断层扫描（PET）的基于伽玛成像（PGI） 技术，从电荷粒子轨道利用二次排放。 PET启用了质子范围 验证是由于正电子发射在电荷颗粒轨道中产生的核的验证。不幸的是，放射线 对该技术的兴趣可以具有半衰期的长度20分钟，其中重要的生物冲洗可以 发生，降低歼灭光子起源与原始质子轨道位置之间的相关性。 PGI 为实时，体内范围验证电荷粒子疗法提供了最有前途的机会， 这种方法中的次要排放是在很短的时间尺度上产生的（picseconds tomilliseConds）。 为了满足对临床体内范围验证系统的需求，劳伦斯·伯克利国家实验室 （lbnl）已经开发了一种基于新型的多刀 - 边缘狭缝准直仪的原型成像系统 能量伽马射线与像素化闪烁检测器读数结合使用。该原型提供了两种 PGI轨道使用此准直仪的尺寸成像。具有50 MEV质子的成像仪的初步评估 梁通过及时的伽马排放量显示了质子轨道的非凡希望，包括子 - 质子范围定量的MM精度与质子统计量相称 治疗。我们建议评估该原型PGI系统在临床相关的束能，梁电流， 以及在临床环境中展示其性能功能的方案。这些评估的数据将 充分表征原型系统的功能，突出显示临床实用程序，还指导设计 实时，体内质子范围验证的高级临床成像系统，在一个小型模块化平台中 可以将患者和龙门人定位在任何治疗方案中。